MEDGENOME TO PRESENT ON ONCOMD, A GENOMICS DATA ANALYSIS AND INTERPRETATION PLATFORM, FOR CANCER DISCOVERY RESEARCH

The MediGenome proprietary platform, currently leveraged by various commercial and academic collaborators in the US, will be presented at AACR 2016.

FOSTER CITY, CALIFORNIA, UNITED STATES, March 30, 2016 /EINPresswire.com/ — Medigenome will present an abstract on its proprietary data analysis and interpretation platform for Cancer discovery research at the AACR Annual Meeting 2016, organised by the American Association of Cancer Research which takes place on April 16-20, 2016 at New Orleans, Louisiana, USA.

OncoMD Cancer Analytics Platform combines tumor mutation profiles, expression signatures, copy number variations, epigenetic alterations and drug sensitivity to create a holistic view of human cancer enabling discovery of new targets for therapy and prognosis. The rich mutational data captured in OncoMD, more than 1.8 million and growing, helps to identify potential T-cell neo-epitopes in different cancers and broadens our understanding of their prevalence in the context of the tumor microenvironment, which could be relevant biomarkers of response for immunotherapy drugs. The powerful data analysis and interpretation offered by OncoMD enable extraction of disease-relevant information from diverse genomics data to guide diagnosis and treatment decisions.

Medigenome offers OncoMD to its customers as an enterprise installation or as a plug-and-play software to the existing pipeline at the customer end. A custom version of the platform, OncoMD Lite, is available as a free license to academic researchers for a limited period.